少関節型乾癬性関節炎患者における インターロイキン-17抑制
Rheumatol Ther. 2023;10(4):849-860 doi: 10.1007/s40744-023-00548-y
Secukinumab reduced disease activity across a range of outcome measures by week 12, with sustained responses through 52 weeks.
June 2023
April 2023
乾癬性関節炎患者におけるトファシチニブ治療の有効性、安全性、継続率の性差: フェーズ3および長期延長試験の事後解析
RMD Open 2023;9:e002718 doi 10.1136/rmdopen-2022-002718
Evidence from two phase 3 RCTs and one LTE shows that while tofacitinib efficacy exceeds placebo in both sexes and is comparable between sexes, males are more likely to achieve minimal disease activity than females.